Johnson Investment Counsel Inc. Lowers Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Johnson Investment Counsel Inc. lowered its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 12.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,436 shares of the specialty pharmaceutical company’s stock after selling 886 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Collegium Pharmaceutical were worth $207,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. ProShare Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 3.3% in the first quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 281 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after buying an additional 300 shares in the last quarter. Texas Permanent School Fund Corp lifted its holdings in shares of Collegium Pharmaceutical by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after buying an additional 369 shares in the last quarter. SummerHaven Investment Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 1.3% in the second quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock worth $1,120,000 after buying an additional 452 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Collegium Pharmaceutical by 1.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock worth $1,137,000 after buying an additional 535 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on COLL shares. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their target price for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright increased their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 31st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Trading Up 2.7 %

Shares of COLL opened at $37.50 on Monday. Collegium Pharmaceutical, Inc. has a twelve month low of $20.95 and a twelve month high of $40.95. The company has a market cap of $1.21 billion, a P/E ratio of 15.63 and a beta of 0.94. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. The company’s fifty day simple moving average is $35.43 and its 200-day simple moving average is $35.40.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same quarter in the prior year, the firm posted $1.13 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, analysts expect that Collegium Pharmaceutical, Inc. will post 5.82 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.